Clinical trial · Interventional
Efficacy of EGF-loaded Self Healing Gel in Treatment of Oral Mucositis
Self Healing Gel as a Vehicle for Recombinant Human Epidermal Growth Factor in Treatment of Oral Mucositis Following Cancer Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cancer treatment, including radiation along with aggressive chemotherapy, increases the patient's survival rate. However, they possess toxic side effects. Oral mucositis is one of the most serious complications of cancer treatment, which occurs in most of patients receiving cancer therapy. Mucositis can dramatically affect the patient's quality of life .Epidermal growth factor (EGF) is a dominant factor in early keratinocyte differentiation, proliferation and migration. However, a major obstacle in most studies is that there isn't prolonged contact between the applied treatment and the oral mucosa to achieve the optimum therapeutic effect. Thus, a new vehicle for EGF is needed to achieve sufficient prolonged contact with oral mucosa. The present project aims at employing EGF as therapeutic agent for mucositis dealing with the challenges of delivery of such macromolecule to the oral mucosa by using self-healing gels to maximize the drug effect.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oral Mucositis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EGF loaded Hydrogel | Drug | — | UNRESOLVED |
| Hydrogel | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- EGF loaded Hydrogel (Gp I)
- description
- 30 patients will receive EGF loaded Hydrogel (Intervention 1) to be applied three times a day for 1weeks.
- interventionNames
- Drug: EGF loaded Hydrogel
- type
- ACTIVE_COMPARATOR
- label
- Hydrogel alone ( Gp II)
- description
- 30 patients will receive Hydrogel alone (Intervention 2) to be applied three times a day for 2 weeks.
- interventionNames
- Drug: Hydrogel
- type
- NO_INTERVENTION
- label
- Control (Gp III)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Eligible patients are those over 18 years of age with WHO grade 3 or 4 oral mucositis receiving radio- or chemotherapy as treatment for head and neck cancer. Exclusion Criteria: * Patients with hematologic malignancies or those with known allergic reactions to the drug.
References
Publications (0)
Data not yet available